ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts. ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company’s product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

BioVest offers cell culture products, instruments, and related contract services to research institutions, biotech firms, and pharmaceutical companies. The company is also developing a therapeutic cancer vaccine for follicular non-Hodgkin's lymphoma that is customized for individual patient use. The candidate, dubbed BiovaxID, is undergoing late-stage clinical trials. Its AutovaxID product is a cell culture instrument designed to ease use of BiovaxID. BioVest is 76% owned by Accentia Biopharmaceuticals. Both BioVest and Accentia filed for Chapter 11 bankruptcy in 2008 and are restructuring their operations.

Laboratorio Chile S.A. makes branded, generic, and OTC drugs, including treatments for respiratory and infectious diseases, as well as cardiovascular, neurological, pain management, and hormone therapy products. Laboratorio Chile also makes such consumer fare as sweetener Marco Sweet, nutritional supplement Esvit-C, and Freshmel antiseptic throat lozenges. The company markets its wares in over a dozen Latin American countries.

Ono Pharmaceutical traces its history back to 1717, though it took its current form in 1947. Ono Pharmaceutical Co., Ltd. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company offers oral medication for the treatment of bronchial asthma, disturbances of peripheral circulation, chronic pancreatitis and overactive bladder, as well as injection drugs for the treatment of acute lung injury, generalized intravascular coagulation syndrome, acute phase cerebral thrombosis and blood pressure regulators used during surgical operations. The Company has four subsidiaries and two associated companies.

Bayhill Therapeutics knows that some immune responses are just way out of line. The biopharmaceutical developer is designing vaccines to eliminate problematic immune responses and restore the immune system to its normal state, known as "tolerance." Its product candidate BHT-3009 is being studied in clinical trials as a treatment for multiple sclerosis while its other leading candidate BHT-3021 is in clinical trials for the treatment of type 1 diabetes. The company's pre-clinical candidate, BHT-3034 is being developed as a treatment for myasthenia gravis, an autoimmune disease that causes interruption in the transmission of nerve impulses to muscles.

Neos Therapeutics makes generic drugs take their time. The contract pharmaceutical manufacturer develops and manufactures branded and generic prescription and OTC pharmaceuticals with an emphasis on time-released formulations. Its products include cold and cough remedies and nutritional supplements. Customers are primarily pharmaceutical distributors and other manufacturers. Neos Therapeutics was slapped hard by the FDA in 2007 for manufacturing unapproved drugs. The action prompted a change in ownership and the company was required to re-file its drug applications in order to resume manufacturing.

Ferring Pharmaceuticals is owned by Swiss drugmaker Ferring Group, which was founded in 1951 and expanded into the US in the early 1980s. Ferring Pharmaceuticals knows that birthing babies is hard work. The company develops and markets a variety of fertility products, including hormone treatments Bravelle, Menopur, Novarel, and Repronex. The company also develops and manufactures products to diagnose and treat ailments in the areas of urology, endocrinology, osteoarthritis, and gastroenterology, including Euflexxa for osteoarthritis of the knee, Prosed for lower urinary tract infections, and Acthrel, a diagnostic agent for Cushing's syndrome.

Generex Biotechnology Corporation company was founded in 1983 and is based in Toronto, Canada. Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company's products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as an aid for dieters. Generex Biotechnology Corporation's under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; morphine and fentanyl products for breakthrough and postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S for the development of a metformin medicinal chewing gum.

Dey, L.P. company, a subsidiary of generic drugmaker Mylan, makes prescription drugs for the treatment of allergies and respiratory diseases. Dey markets EpiPen autoinjectors, used by patients to self-administer epinephrine for severe allergic reactions. Its premeasured unit-dose inhalation products include treatments for asthma and chronic obstructive pulmonary disease (COPD). These treatments, called bronchodialators, are used in air-driven breathing devices called nebulizers and include branded DuoNeb and Perforomist products. It also offers several non-branded generic nebulizer treatments. A direct sales force markets Dey's products to doctors, pharmacies, and wholesalers.

Mymetics Corporation is a biotechnology research and development company focused on fundamental and applied research in the area of human biology and medicine. Mymetics's primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including the human immunodeficiency virus (HIV), the virus that leads to acquired immunodeficiency syndrome (AIDS). Mymetics has also acquired from a scientific partner an advanced malaria vaccine project, which is in phase II clinical trial. Additional applications of Mymetics's research include potential treatments and/or vaccines for malaria, human oncoviral leukemias, multiple sclerosis and organ transplantation. In April 2009, the Company completed the acquisition of Bestewil Holding B.V. and its subsidiary, Virosome Biologicals B.V., from Norwood Immunology Limited.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.